Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Juniper Pharma (JNP) Posts Q4 Loss of $0.19/Share as Revenue Rise to $7.6M
March 10, 2016 6:19 AM ESTJuniper Pharma (NASDAQ: JNP) reported Q4 EPS of ($0.19), $0.17 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $7.89 million and $7.3 million last year.
2015 was a transformative year for Juniper, with strong performance in every aspect of our business, stated Frank Condella, Chief Executive Officer. We made significant progress in R&D, advancing COL-1077 10% lidocaine vaginal gel into the clinic as a... More
